Axoft Secures $55 Million in Series A Funding

Axoft has raised $55 million in an oversubscribed Series A funding led by C.P. Group Innovation with participation from Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment, and Gaorong Ventures.

With more than $60 million in total funding raised, Axoft will use the capital to expand its current clinical trials globally and progress U.S. regulatory approval of its implantable brain-computer interfaces (iBCIs), which have already shown they can safely decode brain signals, and offer a path for improving the standard of care for prognosis and communication in consciousness disorders. Axoft will also use the capital to build a good manufacturing practice (GMP) facility to mass produce its iBCIs.

Neurological disorders are the leading cause of ill health and disability worldwide, affecting one in three people. iBCIs can potentially transform the way these conditions are assessed and treated by providing direct, high-resolution access to neural activity that cannot be captured through traditional exams or external imaging alone. Such neural data can enable the use of artificial intelligence (AI)-driven tools for discovering novel disease biomarkers, supporting more personalized treatments, and powering a new generation of AI models for brain health.

Beyond clinical utility, high-quality neural data is itself an increasingly important frontier. Large-scale, stable recordings from the human brain can deepen our understanding of biological intelligence and provide direct training data for designing and training future AI systems. However, these opportunities have been limited by the shortcomings of conventional neural implants. Existing iBCIs are typically built from rigid materials, which can cause tissue scarring and implant movement over time, which in turn negatively impacts the quality and volume of data that can be collected.

Axoft builds stable, high-density iBCIs to leverage the naturally scalable brain language. The company’s iBCIs are made using its proprietary Fleuron material, which enables high-quality neural data capture over longer periods of time due to the material’s superior biocompatibility. Fleuron is up to 10,000 times softer than the polyimide used in existing iBCIs, and delivers eight times more region access, 32 times more sensor/stimulators per thread than standard flexible probes, and over 60% less signal attenuation than polyimide. Notably, the material can be used for a wide range of applications with hardware-biology interfaces, including biohybrid devices, organ-on-a-chip, microfluidics, and neural interfaces.

“At Axoft, the neural data quality we unlock doesn’t just make iBCIs more effective, it opens the door to minimally invasive surgery, allows access to deeper brain regions, and enables the next generation of AI-driven real-time decoding. Better neural signals are the foundation everything else is built on,” Axoft Co-Founder/CEO Dr. Paul Le Floch stated. “This new funding and strategic support from C.P. Group Innovation allows us to expand our work into global markets. With multiple in-human clinical studies underway, and several industrial and academic organizations already using Fleuron for their own research and development, Axoft is well-positioned to unlock new treatments for patients suffering from neurological disorders while also benefiting the broader biomedical engineering community by making our novel material platform widely available.”

Since announcing its Seed round in 2022, Axoft has made significant progress, including completing first-in-human clinical trials in more than 11 patients worldwide. Research published in Nature (December 2023 and June 2025) demonstrates how the company’s neural interface technology using proprietary materials enables scalable single-cell electrophysiology.

Additional recent milestones include:

• Advancing clinical research collaborations with Mass General Brigham, including using Axoft iBCIs for human cortical mapping, seizure onset mapping around tumors and language recognition tasks.
• Completing a first-in-human clinical study with The Panama Clinic, which involved successfully implanting Axoft iBCIs into four patients undergoing brain tumor resection, and reliably recording 20 minutes of brain activity through different cortical layers and subcortical regions.
• Commercially launching Fleuron via an exclusive licensing agreement with Stanford University, which makes the ISO-10993 compliant material available for purchase for biomedical applications.
• Securing a joint development agreement with Kayaku Advanced Materials, which involves milestone payments and licensing opportunities for Axoft’s Fleuron material.
• Receiving grant funding from the Massachusetts Manufacturing Innovation Initiative, which Axoft is using to build a GMP facility for mass production of its iBCIs and proprietary materials.
• Introducing Fleuron for Microfluidics, a new material formulation designed for rapidly prototyping microfluidic devices using soft lithography methods similar to Polydimethylsiloxane (or PDMS).
• Opening a subsidiary in Grenoble, France, which allows Axoft to tap into the area’s deep tech, medtech and neuroscience ecosystem, build a local team, and launch additional pre-clinical and clinical projects.

Axoft plans to build out its GMP cleanroom in Boston and expand its software engineering, microfabrication, and chemistry teams.

Co-founded in 2021 by Dr. Paul Le Floch, Dr. Tianyang Ye and Prof. Jia Liu, Axoft is building iBCIs that leverage bio-inspired materials to enable a seamless interface between the brain and electronics, and allow for measurement and stimulation at high-resolution in any brain region. Headquartered in Cambridge, Mass., Axoft aims to unlock new treatments for patients suffering from neurological disorders by producing iBCIs that answer critical unmet needs.